Dominic Titone, MD
Critical Care Medicine · Lakewood, CONPI 1184816159
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,215 of the $4,632 with a category attached, or 69.4%. 19 manufacturers reported payments, led by Chiesi USA, Inc. at 40.8% of the total. 2025 is the largest year on record at $2,083, more than ten times the $166 reported in 2019.
Across 52 payments — averaging $89.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$2K
- Modernatx, Inc.$2K
- GSK$239
- AstraZeneca$144
- Inspire Medical Systems, Inc.$129
- Actelion Pharmaceuticals US, Inc.$92
- plus $371 from 13 others
Across 650 payments — averaging $2939.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$1M
- Boehringer Ingelheim$281K
- AstraZeneca$270K
- Genentech, Inc.$146K
- GSK$40K
- Teva Pharmaceuticals USA, Inc.$29K
- plus $106K from 6 others
What the payments were for
- Travel & lodging$3,21569%
- Food & beverage$1,41531%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 2 | $1,890 |
| Modernatx, Inc. | 3 | $1,767 |
| GSK | 12 | $239 |
| AstraZeneca | 8 | $144 |
| Inspire Medical Systems, Inc. | 3 | $129 |
| Actelion Pharmaceuticals US, Inc. | 4 | $92 |
| Boehringer Ingelheim | 2 | $61 |
| Bayer | 3 | $59 |
| Sanofi | 2 | $37 |
| Novartis | 2 | $33 |
| Amgen | 1 | $29 |
| Mylan Specialty L.p. | 2 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Resmed Corp | 1 | $21 |
| Merck | 1 | $19 |
| United Therapeutics Corporation | 2 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
| Electromed, Inc. | 1 | $14 |
How this compares
$4,632 in reported general payments places this provider in the 80th percentile of 141 critical care medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 12 | $179,144 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 170 | $147,364 |
| NucalaMepolizumab | 11 | $47,084 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $41,642 |
| Spiriva RespimatTiotropium Bromide | 40 | $36,959 |
| Spiriva HandihalerTiotropium Bromide | 17 | $12,866 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $12,009 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $11,833 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $8,496 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $6,282 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $6,083 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 112 | $3,141 |
| Fluticasone Propionate | 39 | $1,044 |
| Omeprazole | 48 | $879 |
| Ventolin HfaAlbuterol Sulfate | 15 | $818 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta | $239 | $242,373269 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $61 | $228,11273 claims |
| AstraZenecaSymbicort | $144 | $11,83330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 141 critical care medicine providers in Colorado.
Other critical care medicine in Lakewood
- Mary ElmasriLakewood$4K
- Alexandra SmartLakewood$3K
- Kolene BaileyLakewood$2K
- Paula DennenLakewood$1K
- Peter RileyLakewood$985
- Joshua LeeLakewood$597
- Matthew DickinsonLakewood$594
- Peter HountrasAurora$86K
- Paul WischmeyerAurora$78K
- Chakradhar KotaruGreenwood Village$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.